Interestingly, LILRB2 antagonism was suggested to reprogram tumor-associated myeloid cells, to enhance pro-inflammatory responses and to promote antitumor effects of T cell immune checkpoint inhibitors (39). This evidence concerns the gene LILRB2 and neoplasm.